Emerging B7H3 ADCs in SCLC

CME

Clinical Focus in SCLC: Emerging Insights on B7-H3–Targeted ADCs and Their Transformative Potential in Clinical Practice

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: May 14, 2025

Expiration: November 13, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following most accurately reflects the rationale for targeting B7-H3 in SCLC with ADCs?

2.

Which of the following outcomes was reported from the phase II IDeate-Lung01 trial evaluating ifinatamab deruxtecan (I-DXd) in patients with previously treated extensive-stage SCLC (ES-SCLC)?

3.

You are discussing a patient with ES-SCLC with your clinical team and they are considering clinical trial enrollment. Which of the following eligibility requirements would you discuss with them about the phase III IDeate-Lung 02 trial?